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Repeatability of Meibomian Gland Contrast, a Potential
Indicator of Meibomian Gland Function
Thao N. Yeh, OD, MPH,*† and Meng C. Lin, OD, PhD*†
Purpose: Meibomian gland contrast may be a potential indicator of
gland health, especially among isotretinoin users. We aimed to
develop a repeatable and reliable method for measuring Meibomian
gland contrast from meibography images.
Methods: Lower lid (LL) and upper lid (UL) meibography were
captured with the OCULUS Keratograph 5M (OCULUS, Inc) at 2
visits under the following 4 conditions: face centered with room
lights on (C), left-turned face (L), right-turned face (R), and face
centered with room lights off (CLO). Contrast was measured with
Fiji (v2.0.0-rc-59). Coefﬁcient of repeatability and limits of agree-
ment (LOA) were determined using Bland-Altman plots.
Results: A total of 512 meibography images from 16 subjects (age6
SD = 24.86 5.2 years; 13 female patients) were collected. Coefﬁcient
of repeatability between visits was 10.5 for UL and 14.9 for LL.
Lower and upper LOA, respectively, for UL, compared with condition
C, were210.9 [95% conﬁdence interval (CI),213.5 to28.3] and 6.2
(95% CI, 3.6–8.8) for L; 211.0 (95% CI, 213.8 to 28.1) and 7.0
(95% CI, 4.2–9.8) for R; and 29.0 (95% CI, 211.6 to 26.5) and 7.2
(95% CI, 4.7–9.8) for CLO. Lower and upper LOA, respectively, for
LL, compared with condition C, were 218.1 (95% CI, 222.6 to
213.5) and 11.0 (95% CI, 6.5–15.5) for L; 215.3 (95% CI,219.2 to
211.3) and 9.9 (95% CI, 6.0–13.9) for R; and212.0 (95% CI,215.1
to 28.8) and 8.2 (95% CI, 5.0–11.3) for CLO.
Conclusions: Meibomian gland contrast is a repeatable and
reliable measure for changes in Meibomian gland contrast greater
than 11 in the UL and 18 in the LL.
Key Words: tear lipid layer, meibomian gland, tear ﬁlm stability,
meibomian gland expressibility, meibography, evaporative dry eye,
meibomian gland dysfunction, meibomian gland contrast, isotreti-
noin, 13-cis-retinoic acid, accutane, contrast, meibomian gland
intensity, intensity, dry eye, dry eye disease, repeatability, limits of
agreement
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Meibomian gland dysfunction (MGD) is believed to bethe most common cause of ocular dryness symptoms.1
Extensive effort has been made to understand the patho-
physiology of MGD-induced evaporative dry eye, partic-
ularly the relationship between Meibomian gland dropout
and meibum output in vivo. Meibomian gland dropout
implies partial or total gland loss or atrophy, and it has
been estimated by meiboscopy and meibography. Meibo-
scopy allows visualization of Meibomian glands by
retroillumination of the eyelids, usually with a penlight
or transilluminator, whereas meibography also includes
photo-documentation. More recent meibography innova-
tions include biomicroscopes and corneal topographers
equipped with infrared cameras that produce images with
better contrast between the Meibomian glands and sur-
rounding tarsal plate and tissues. More advanced systems
integrate both retroillumination and infrared photo-
documentation to take advantage of both methods.
When evaluating meibography images, we make the
assumptions that the glands, which appear as bright linear
structures on meibography, are supposed to extend the full
length of the tarsal plate, and when they do not, they are
assumed to have functional gland loss, or atrophied. The
degree of atrophy is most commonly assessed as a percentage
of gland loss area (eg, space unoccupied by Meibomian
glands) compared with the presumed full area of the tarsal
plate. The estimated percentage can then be assigned a grade
using one of several ordinal scales to represent severity.2–8
Although grading atrophy is useful, especially in cases like
obstructive MGD in which glands appear shorter because of
hyporeﬂectivity proximal to the blockage, it may not be as
useful in cases of hyposecretory MGD, where a global
suppression of meibum production may result in overall
dimming or fading of whole glands, not just shortening. In
such instances, we would expect to see decreased intensity of
all Meibomian glands along their full lengths but would be
unable to characterize them using the existing Meibomian
gland atrophy grading system.
In this study, we aim to demonstrate that measuring
contrast in the region of the central 5 Meibomian glands
from meibography images captured and processed with the
OCULUS Keratograph 5M is repeatable between visits and
show good agreement between different head positions and
room lighting conditions. Having an objective, reliable,
and repeatable grading method can be valuable for detect-
ing subtle changes in meibography because of age, disease,
or intervention, particularly when Meibomian gland length
may not change.
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METHOD
Subjects
Study participants were recruited from the University of
California, Berkeley campus and surrounding community, and
came for 2 visits at the Clinical Research Center in the School of
Optometry. Participants were required to be 18 years or older and
free of ocular infection, inﬂammation, or disease and systemic
disease. Participants were excluded if using oral or ophthalmic
medications and if their medical history changed between visits.
Written informed consent was obtained from all study partic-
ipants, and the study adhered to the tenets of the Declaration of
Helsinki. The study protocol was approved by the University of
California, Berkeley, Ofﬁce for Protection of Human Subjects.
Meibography Images
Meibography of upper (UL) and lower (LL) eyelids
from both eyes of study participants were captured with the
OCULUS Keratograph 5M (OCULUS, Inc, Arlington, WA),
which produces 2 images: raw and processed. The OCULUS-
processed images have increased contrast between the
Meibomian glands and surrounding tissues and are the ones
analyzed in this study. Meibography was captured at 2
separate visits under the following 4 conditions: face centered
with room lights on, face turned left, face turned right, and
face centered with room lights off. Using Fiji (version 2.0.0-
rc-59/1.51k),9 an image processing package (ImageJ with
plugins), mean pixel intensity (gray scale: 0–255) was measured
of segmented lines drawn along the central 5 Meibomian glands
(Fig. 1A) and along the background regions between the
Meibomian glands measured (Fig. 1B). The difference between
mean intensity along the Meibomian glands and mean intensity
along background regions between the MGs was deﬁned
as contrast.
Statistical Methods
Using previously published methods, the sample size
was estimated to be 13 study participants, with 16 UL and
16 LL measurements per participant over 2 visits.10 The
coefﬁcient of repeatability was measured for the same
measurement conditions between visits, and the limits of
agreement (LOA) for face turned left, face turned right, and
face centered with room lights off when each are compared




Meibography images of 16 subjects (age6 SD = 24.86
5.2 years) were collected over 2 visits (separated by 1–4 days)
under 4 different conditions for both upper and lower eyelids of
FIGURE 1. Contrast is the difference in mean pixel intensity of (A) central 5 glands (AvgIntG) (yellow lines represent glands; arrows
point to leftmost measured gland) and (B) background Intensity between glands (AvgIntB) (yellow lines represent background space;
arrows point to space between the 2 leftmost glands). AvgIntG, average of 5 glands; AvgIntB, average of 4 background regions.
TABLE 1. Mean Contrast for Each Test Condition at Each Visit
Visit 1 Visit 2
Face centered with room lights on
Upper lid 40.8 6 12.2 40.7 6 12.9
Lower lid 60.1 6 19.1 61.4 6 20.9
Face turned left
Upper lid 39.1 6 12.0 37.7 6 12.3
Lower lid 55.6 6 20.8 58.8 6 22.1
Face turned right
Upper lid 39.3 6 14.1 38.2 6 13.5
Lower lid 57.0 6 18.7 59.1 6 20.6
Face centered with room lights off
Upper lid 39.0 6 11.0 40.7 6 12.9
Lower lid 57.7 6 18.5 60.0 6 18.3
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both eyes, totaling 512 images. The study population included
13 female patients and 14 Asians.
Repeatability
The mean (6SD) contrast for the LL was consistently
higher than that for the UL (Table 1). Comparing measure-
ments taken between visits, the average differences in contrast
between visits and coefﬁcients of repeatability, respectively,
were 20.21 6 5.28 and 10.53 for the upper eyelid, 2.20 6
7.48 and 14.91 for the lower eyelids, and 21.00 6 6.58 and
13.13 when combining both upper and lower eyelids. The
differences versus means plots for the upper and lower eyelids
are presented in Figure 2. In general, the contrast measure-
ment exhibited best repeatability with the upper eyelid
meibography images compared with the LL meibography
images.
Limits of Agreement
The mean Meibomian gland and background intensities
as well as mean contrast for each lid under each of the 4
previously deﬁned conditions are reported in Table 2. Using
the centered position with room lights on as the reference,
mean differences in Meibomian gland contrast were
estimated against other head positions/room conditions
for the upper eyelid, lower eyelid, and both lids combined.
The differences versus means plots for these comparisons
are presented in Figure 3. In general, the mean differences
in contrast were lower for the upper eyelid than for the
lower eyelid.
For the upper eyelid, the lower and upper LOA
compared with the reference condition were 210.9 [95%
conﬁdence interval (CI): 213.5 to 28.3] and 6.2 (95% CI,
3.6–8.8), respectively, for left-turned faces; 211.0 (95% CI,
213.8 to 28.1) and 7.0 (95% CI, 4.2–9.8), respectively, for
FIGURE 2. Contrast differences versus means plots comparing visit 1 to visit 2 for (A) upper lid and (B) lower Lid.
TABLE 2. Mean Meibomian Gland Intensity, Background Intensity, and Contrast for Each Eyelid Under Each Test Condition
Upper Eyelid Lower Eyelid
Mean 6 SD Range Mean 6 SD Range
Center
Gland intensity 187.5 6 17.7 157.9–223.7 189.6 6 18.3 152.4–220.7
Background intensity 146.7 6 12.9 123.7–173.8 129.5 6 24.6 44.9–171.8
Contrast 40.7 6 12.4 15.0–64.5 60.7 6 19.6 29.3–125.9
Left
Gland intensity 181.8 6 18.3 144.7–215.9 186.6 6 15.9 158.1–216.9
Background intensity 142.7 6 17.3 96.9–183.4 130.9 6 24.1 47.6–179.0
Contrast 38.4 6 11.9 11.6–58.5 57.2 6 21.3 27.4–141.4
Right
Gland intensity 182.6 6 19.6 143.4–216.3 186.5 6 17.3 150.7–219.0
Background intensity 143.3 6 14.2 116.5–172.6 129.5 6 23.0 50.9–177.4
Contrast 38.8 6 13.4 13.5–64.6 58.1 6 19.2 22.3–124.8
Center–room lights off
Gland intensity 181.0 6 15.7 154.2–217.6 187.7 6 19.5 149.5–223.3
Background intensity 142.0 6 14.8 113.7–171.4 130.0 6 28.9 23.1–174.4
Contrast 39.8 6 11.7 11.8–61.9 58.8 6 18.0 29.1–124.4
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right-turned faces; and 29.0 (95% CI, 211.6 to 26.5) and
7.2 (95% CI, 4.7–9.8), respectively, for centered faces with
room lights off (Table 3). For the lower eyelid, the lower and
upper LOA compared with the reference condition were
218.1 (95% CI, 222.6 to 213.5) and 11.0 (95% CI, 6.5–
15.5), respectively, for left-turned faces; 215.3 (95% CI,
219.2 to 211.3) and 9.9 (95% CI, 6.0–13.9), respectively,
for right-turned faces; and 212.0 (95% CI, 215.1 to 28.8)
and 8.2 (95% CI, 5.0–11.3), respectively, for centered
faces with room lights off. When both upper and lower
eyelids were combined, the lower and upper LOA
compared with the reference condition were 214.8 (95%
CI, 217.4 to 212.2) and 8.9 (95% CI, 6.4–11.5),
respectively, for left-turned faces; 213.2 (95% CI,
215.5 to 210.8) and 8.6 (95% CI, 6.2–10.9), respec-
tively, for right-turned faces; and 210.5 (95% CI, 212.5
to 28.6) and 7.7 (95% CI, 5.8–9.7), respectively, for
centered faces with room lights off.
DISCUSSION
This study aimed to determine the repeatability and
reliability of measuring meibography contrast of the central-
5-gland region of both upper and lower eyelids. Measure-
ments were taken at 2 separate visits to determine repeatability
and under 4 different conditions for both eyes to estimate the
LOA. We found that the coefﬁcient of repeatability was 10.5
for the upper eyelid and 14.9 for the lower eyelid, when
comparing images taken under same conditions but at
different visits. Furthermore, the LOA for the upper eyelid
were similar when comparing centered head position to left
(210.9 to 6.2) or right (211.0 to 7.0) head positions and were
smallest compared with centered head position with room
lights off (29.0 to 7.2). These results suggest that 95% of
individuals will have a difference in contrast in the upper
eyelid between approximately 211.0 and 7.2, at the most,
based on the extreme values of the UL LOA. For the lower
eyelid, the LOA were all further apart than those for the upper
FIGURE 3. Contrast differences versus means plots for the upper eyelids (A–C), lower eyelids (D–F), and upper and lower lids
combined (G–I). Plots comparing left against centered head positions are (A), (D), and (G); right against centered head positions
are (B), (E), and (H); and centered head positions with room lights off against room lights on are (C), (F), and (I).
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eyelid, and gap was greatest when comparing the centered
head position with left (218.1 to 11.0) or right (215.3 to
9.9) head positions and was smaller compared with centered
head position with room lights off (212.0 to 8.2). Based on
the extreme values of the LL LOA, the results suggest that
95% of individuals will have a difference in contrast in the LL
between approximately 218.1 and 8.2, at the most. When the
data for both upper and lower eyelids were combined, the
LOA were furthest apart when comparing the centered head
position with the left head position (214.8 to 8.9) and right
head position (213.2 to 8.6) and were closest compared
with the centered head position with room lights off (210.5
to 7.7).
It is unclear what is exactly seen on meibography
images (measured at 840 nm), but we know that many
organic compounds, such as lipids, are highly reactive to
infrared light. This is the basis for infrared spectroscopy,
which uses medium infrared wavelengths to produce
TABLE 3. Limits of Agreement (LOA, Matched by Visit) for Upper Lids, Lower Lids, and all Lids
Left Versus Center With Lights On Right Versus Center With Lights On Center With Lights Off Versus Center With Lights On
Lower LOA Upper LOA Lower LOA Upper LOA Lower LOA Upper LOA
Upper lid
LOA 210.9 6.2 211.0 7.0 29.0 7.2
SE 1.3 1.3 1.4 1.4 1.2 1.2
95% CI 213.5 to 28.3 3.6 to 8.8 213.8 to 28.1 4.2 to 9.8 211.6 to 26.5 4.7 to 9.8
Lower lid
LOA 218.1 11.0 215.3 9.9 212.0 8.2
SE 2.2 2.2 1.9 1.9 1.5 1.5
95% CI 222.6 to 213.5 6.5 to 15.5 219.2 to 211.3 6.0 to 13.9 215.1 to 28.8 5.0 to 11.3
Combined lids
LOA 214.8 8.9 213.2 8.6 210.5 7.7
SE 1.3 1.3 1.2 1.2 1.0 1.0
95% CI 217.4 to 212.2 6.4 to 11.5 215.5 to 210.8 6.2 to 10.9 212.5 to 28.6 5.8 to 9.7
FIGURE 4. Isotretinoin patient upper lid meibography images at (A) baseline and (B) after 6 months of treatment, and (C)
contrast Changes during treatment.
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qualitative information on functional groups used to identify
compounds.12 Infrared imaging is also used to visualize
subretinal lipid deposits, such as drusen, at wavelengths
greater than 800 nm.13 Hartnett and Elsner14 found that IR
imaging at 865 nm of the retina belonging to patients with
exudative age-related macular degeneration provided the best
visualization of drusen, as well as numerous other subretinal
deposits that were not apparent clinically or through other
methods such as ﬂuorescein angiography and indocyanine
green angiography. With respect to meibography, the con-
sensus is that the highly reﬂective linear structures represent
lipid-ﬁlled Meibomian gland ducts connected by ductules to
acini containing lipid-producing meibocytes. It is unclear
whether the reﬂectivity of the presumed glands is an indicator
of gland function, but the case presented in Figure 4 suggests
that it may, in fact, be true. Figure 4 presents a case belonging
to a 19-year-old Asian male patient who received a course of
isotretinoin treatment. Images were taken before commencing
treatment (Fig. 4A) and after 5 months of treatment (Fig. 4B).
It is notable that the reﬂectivity of the glands, assessed using
the contrast measurement described in this article, decreased
during treatment and then increased after discontinuing
treatment. It is interesting to note that the length of the
glands remained fairly constant throughout, so measuring
percent atrophy would have overlooked an important change
occurring inside the glands. Studies have shown that iso-
tretinoin shrinks human sebaceous glands, increases the
presence of undifferentiating cells, and inhibits sebum pro-
duction.15,16 In relation to immortalized human Meibomian
gland epithelial cells, 13-cis-retinoic acid was shown to
increase cell death and inhibits cell proliferation.17 Therefore,
the decreased reﬂectivity of the Meibomian glands, especially
in isotretinoin cases, may be an indication of shrinking
meibocytes, decreased cell proliferation, and, as a result,
decreased meibum production.
In summary, measuring the contrast in the central-5-
gland region of meibography images is a repeatable and
reliable method for potentially tracking longitudinal changes
to Meibomian glands because of age, disease, or intervention,
particularly when systemic effects are expected. Contrast
changes greater than 11 units in the upper eyelid or 18 units in
the lower eyelid are less likely because of head position, room
lighting, or inherent variations, but would more likely be
because of physiologic changes within the Meibomian glands.
As evidenced by the isotretinoin case in Figure 4, contrast can be
useful in monitoring patients using other medications known to
be associated with MGD, including antidepressants/antipsy-
chotics, antiandrogens, and antihistamines.18–23 It would also
be beneﬁcial in identifying changes that may occur with diseases
known to be associated with MGD, such as androgen deﬁciency,
atopy, psoriasis, and rosacea.21,22,24–27
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